Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,412,600 | 3,494,900 | 2,154,300 | 722,000 | 3,953,600 |
| Depreciation Amortization | 482,900 | 356,500 | 234,800 | 114,100 | 421,000 |
| Income taxes - deferred | -757,300 | -477,100 | -308,500 | -190,400 | -837,800 |
| Accounts receivable | -554,000 | -436,200 | -47,300 | 446,800 | -338,800 |
| Other Working Capital | -618,300 | -531,900 | -468,000 | 440,500 | -94,100 |
| Other Operating Activity | 1,454,600 | 751,500 | 301,200 | -20,500 | 1,490,100 |
| Operating Cash Flow | $4,420,500 | $3,157,700 | $1,866,500 | $1,512,500 | $4,594,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,590,100 | -2,219,200 | -1,886,700 | -1,525,300 | -2,203,800 |
| PPE Investments | -735,800 | -536,200 | -294,300 | -133,900 | -718,600 |
| Net Acquisitions | -16,500 | -5,000 | -5,000 | N/A | -54,900 |
| Purchase Sale Intangibles | -125,700 | -58,300 | -58,300 | -27,900 | -207,800 |
| Other Investing Activity | -125,700 | -58,300 | -58,300 | -27,900 | -207,800 |
| Investing Cash Flow | $-2,468,100 | $-2,818,700 | $-2,244,300 | $-1,687,100 | $-3,185,100 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,465,300 | 1,374,400 | 1,119,700 | 682,100 | 1,145,500 |
| Common Stock Repurchased | -3,632,400 | -2,406,000 | -1,550,700 | -635,000 | -2,935,600 |
| Other Financing Activity | -33,400 | -33,400 | 0 | 0 | 0 |
| Financing Cash Flow | $-2,200,500 | $-1,065,000 | $-431,000 | $47,100 | $-1,790,100 |
| Exchange Rate Effect | -700 | 0 | -800 | -500 | -400 |
| Beginning Cash Position | 2,737,800 | 2,737,800 | 2,737,800 | 2,737,800 | 3,119,400 |
| End Cash Position | 2,489,000 | 2,011,800 | 1,928,200 | 2,609,800 | 2,737,800 |
| Net Cash Flow | $-248,800 | $-726,000 | $-809,600 | $-128,000 | $-381,600 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,420,500 | 3,157,700 | 1,866,500 | 1,512,500 | 4,594,000 |
| Capital Expenditure | -755,900 | -556,300 | -314,400 | -133,900 | -718,600 |
| Free Cash Flow | 3,664,600 | 2,601,400 | 1,552,100 | 1,378,600 | 3,875,400 |